User profiles for Theodore G Liou

Theodore G Liou

University of Utah
Verified email at utah.edu
Cited by 9181

Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management …

…, A Frost, RJ Barst, DB Badesch, CG Elliott, TG Liou… - Circulation, 2010 - Am Heart Assoc
Background— Factors that determine survival in pulmonary arterial hypertension (PAH) drive
clinical management. A quantitative survival prediction tool has not been established for …

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry

…, HW Farber, AE Frost, RJ Barst, RL Benza, TG Liou… - Chest, 2010 - Elsevier
Background The Registry to EValuate Early And Long-term pulmonary arterial hypertension
disease management (REVEAL Registry) was established to provide updated …

Predictive 5-year survivorship model of cystic fibrosis

TG Liou, FR Adler, SC FitzSimmons… - American journal of …, 2001 - academic.oup.com
The objective of this study was to create a 5-year survivorship model to identify key clinical
features of cystic fibrosis. Such a model could help researchers and clinicians to evaluate …

The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries

…, RL Benza, CG Elliott, HW Farber, A Krichman, TG Liou… - Chest, 2011 - Elsevier
Background REVEAL (The Registry to Evaluate Early and Long-term Pulmonary Arterial
Hypertension Disease Management) provides current demographics of patients with group 1 …

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

PA Flume, TG Liou, DS Borowitz, H Li, K Yen… - Chest, 2012 - Elsevier
… As the principal investigator for the Therapeutic Development Network Center at the
University of Utah, Dr Liou has received funding to participate in trials of novel treatments for CF …

Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry

…, MD McGoon, HW Farber, AE Frost, TG Liou… - Chest, 2011 - Elsevier
Background Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder.
Despite the emergence of effective therapy, PAH is commonly at an advanced stage when …

Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS

…, BE Troyer, RE Whatley, TG Liou… - American journal of …, 1998 - atsjournals.org
A randomized, controlled clinical trial was performed with patients with acute respiratory
distress syndrome (ARDS) to compare the effect of conventional therapy or inhaled nitric oxide (…

Insulin therapy to improve BMI in cystic fibrosis–related diabetes without fasting hyperglycemia: results of the Cystic Fibrosis Related Diabetes Therapy Trial

…, M Zorn, B Slovis, J Pilewski, E Tullis, TG Liou… - Diabetes …, 2009 - Am Diabetes Assoc
OBJECTIVE Cystic fibrosis–related diabetes (CFRD) without fasting hyperglycemia (CFRD
FH−) is not associated with microvascular or macrovascular complications, leading to …

[HTML][HTML] Lung transplantation and survival in children with cystic fibrosis

TG Liou, FR Adler, DR Cox… - New England Journal of …, 2007 - Mass Medical Soc
Background The effects of lung transplantation on the survival and quality of life in children
with cystic fibrosis are uncertain. Methods We used data from the US Cystic Fibrosis …

Survival effect of lung transplantation among patients with cystic fibrosis

TG Liou, FR Adler, BC Cahill, SC FitzSimmons… - Jama, 2001 - jamanetwork.com
ContextPatients with cystic fibrosis (CF) are the second largest group of lung transplant
recipients in the United States. The survival effect of transplantation on a general CF population …